Efficacy and safety of edoxaban for lower-extremity venous thrombosis in patients with lung cancer - Prospective observational study-

Efficacy and safety of edoxaban for lower-extremity venous thrombosis in patients with lung cancer - Prospective observational study- - Efficacy and safety of edoxaban for lower-extremity venous thrombosis in patients with lung cancer - Prospective observational study-

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000027152

Enrollment

Registered

2017-04-26

Start date

2017-04-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer associated lower-extremity venous thrombosis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) lung cancer patients with image-diagnosed lower-extremity deep vein thrombosis (2) patients scheduled to begin treatment with edoxaban (3) written informed consent

Exclusion criteria

Exclusion criteria: (1) treatment with thrombectomy or thrombolytic therapy (2) Inappropriate patients in this study

Design outcomes

Primary

Measure	Time frame
Reduction of thrombus(2, 8, 16 weeks)	—

Countries

Japan

Contacts

Public ContactKageaki Taima

Hirosaki University Graduate School of Medicine Department of Respiratory Medicine

taima0305@hotmail.com+81-172-33-5111

Outcome results